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INTRODUCTION
Identification of a nuclear protein and an orphan receptor as 
IL-33 and IL-33 receptor
Interleukin-33 (IL-33), a member of the IL-1 cytokine family, 
is considered to be crucial for the induction of T-helper type (Th) 
2 cell-dominant immune responses such as host defense against 
nematodes and allergic diseases.
1 IL-33 was originally identi-
fied as “DVS27” , a gene upregulated in vasospastic cerebral ar-
teries after subarachnoid hemorrhage
2 and as a nuclear factor, 
“nuclear factor from high endothelial venules (NF-HEV)” , which 
is expressed in endothelial cell nuclei.
3
IL-33 receptor was first identified as an IL-1 receptor-like mol-
ecule and termed as ST2 (the gene symbol was termed as IL-
1RL1) by Tominaga in 1989.
4 ST2 was subsequently found to be 
preferentially expressed in Th2 cells and started to attract many 
researchers involved in allergy.
5 In 2005, DVS27 was rediscov-
ered as the 11th member in the IL-1 family of cytokines, which 
includes IL-1α, IL-1β, and IL-18, by computationally searching 
for the sequences containing β-trefoil structure seen in IL-1- and 
FGF-like proteins, and termed as IL1F11 or IL-33.
6
IL-33 receptor and signal transduction
As the receptors for the other IL-1-related cytokines, the IL-33 
receptor is formed heterodimeric molecules consisting of ST2 
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and IL-1 receptor accessory protein (IL-1RAcP; Fig. 1). IL-
1RAcP is also known as a common component of receptors for 
IL-1α, IL-1β, IL-1F6, IL-1F8, and IL-1F9.
1
The two major products of ST2 genes (IL1RL1), i.e., transmem-
brane form ST2 (ST2 or ST2L) and soluble form ST2 (sST2) are 
produced by alternative splicing under the control of two dis-
tinct promoters. ST2 is considered to be the functional compo-
nent for induction of IL-33 bioactivities, while sST2 act as a de-
coy receptor for IL-33 like soluble IL-1Rs for IL-1.
1
The signal transduction downstream of IL-33 receptor is me-
diated by common adapter molecules to that of the other IL-1 
receptor family such as IL-1R and IL-18R. The binding of IL-33 
to IL-33 receptor results in the recruitment of MyD88 to the 
Toll-interleukin-1 receptor domain in cytoplasmic region of 
ST2, leading to the induction of inflammatory mediators by ac-
tivating transcription factors such as NF-κB and AP-1 through 
IRAK, TRAF6 and/or MAP kinases, like other IL-1 family recep-
tor or Toll-like receptor (TLR) activation.
6
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Interleukin-33 (IL-33) is the 11th member of IL-1 cytokine family which includes IL-1 and IL-18. Unlike IL-1β and IL-18, IL-33 is suggested to function 
as an alarmin that is released upon endothelial or epithelial cell damage and may not enhance acquired immune responses through activation of in-
flammasome. ST2, a IL-33 receptor component, is preferentially expressed by T-helper type (Th) 2 cells, mast cells, eosinophils and basophils, com-
pared to Th1 cells, Th17 cells and neutrophils. Thus, IL-33 profoundly enhances allergic inflammation through increased expression of proallergic cy-
tokines and chemokines. Indeed, IL-33 and its receptor genes are recognized as the most susceptible genes for asthma by several recent genome-
wide association studies. It has also recently been shown that IL-33 plays a crucial role in innate eosinophilic airway inflammation rather than ac-
quired immune responses such as IgE production. As such, IL-33 provides a unique therapeutic way for asthma, i.e., ameliorating innate airway in-
flammation.
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THE SOURCES AND THE TARGETS OF IL-33
IL-33 as a alarmin
In contrast to the other IL-1 family cytokines except IL-1α, IL-
33 is localized to the nucleus of human epithelial and endothe-
lial cells
2 and mouse bone-marrow derived cultured mast cells
7 
by binding to chromatin via a homeodomain (helix-turn-helix-
like motif) and nuclear localization signal in amino-terminus.
8 
Although the pathophysiological role of IL-33 as a nuclear fac-
tor is not fully understood, IL-33 binds to the acidic pocket of 
dimeric histone H2A-H2B at the surface of nucleosomes, result-
ing in the suppression of the gene transcription at least in the in 
vitro reporter assay system.
8
During host defense against pathogens, innate-type immune 
cells recognize pathogen-associated molecular patterns via 
TLRs, resulting in induction of inflammation. In addition, en-
dogenous proinflammatory factors called “damage associated 
molecular patterns (DAMPs)” (also called “alarmin”), which 
are released by necrotic cells in tissue injury during trauma and/
or infection, also provoke local and/or systemic inflammation 
by alerting acquired-type immune cells as an endogenous dan-
ger signal.
9 For example, high-mobility group box 1 (HMGB1), 
which is originally identified as a nuclear factor as a transcrip-
tional regulator, is released by macrophages in response to lipo-
polysaccharide, leading to the induction of inflammation.
10 Like 
HMGB1, recent several lines of evidence suggest that IL-33, 
which also localizes in nucleus, act as a DAMP/alarmin.
11
IL-33 was originally considered to be secreted by the activa-
tion of NACHT, LRR and PYD containing protein (NLRP)-me-
diated inflammasomes like IL-1β and IL-18 since it is cleaved 
from pro-IL-33 by caspase-1 in vitro.
6 However, pro-IL-33 does 
not have a typical cleavage site seen in pro-IL-1β and -IL-18, 
and caspase-1 was found to proteolytically cleave pro-IL-33 at 
the cytokine motif, but not the intermediate region between 
helix-turn-helix motif and cytokine motif, resulting in the inac-
tivation of IL-33.
11-13 Like caspase-1, both caspase-3 and cas-
pase-7 have an ability to cleave pro-IL-33 during apoptosis, in 
which apoptotic cells do not induce inflammation generally, 
and the processed IL-33 by these caspases do not have biologi-
cal activities.
11,12
On the other hand, biologically active pro-IL-33 can be released 
by necrotic cells without any processes by caspase-1, -3, -7, -8, 
and calpain.
7,11-13 For example, pro-IL-33 can induce mouse 
mast cell activation to produce cytokines.
13 These observations 
suggest that pro-IL-33 released by necrotic cells during tissue 
injury may have a potential role in induction of inflammation 
as a DAMP/alarmin.
IL-33 is an epithelial-mesenchymal cytokine manipulating 
inflammatory responses
Asthma is an inflammatory disease characterized by infiltra-
tion of the airway wall with a variety of immune cells and in-
flammatory cells such as Th2 cells, mast cells and eosinophils. 
However, a key component of asthma is the structural change 
that involves all of the elements of the airway wall associated 
with activation of the epithelial-mesenchymal trophic unit.
14
Activated epithelial and mesenchymal cells generate a range 
of growth factors associated with airway remodeling and cyto-
kines manipulating the immune response. Although IL-33 is 
present in the nuclei of various cell types, epithelial cells
15 and 
endothelial cells
16 are recognized as the major sources of the 
cytokine especially when considering the event of tissue dam-
age.
Thus, like thymic stromal lymphopoietin (TSLP),
17 IL-33 is 
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Fig. 1.  Heterodimeric receptors for interleukin-1 (IL-1) family cy-
tokines. IL-1 receptor and IL-33 receptor share IL-1 receptor ac-
cessory protein (IL-1RAcP) amplifying the receptor signaling.IL-33 and Airway Inflammation AAIR 
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now recognized as an epithelial-mesenchymal-derived cyto-
kine manipulating inflammatory and/or immune responses.
Target cells of IL-33
Th2 cells
It is well established that IL-4 is a key cytokine for the differen-
tiation of Th2 cells from naïve CD4
+ T cells. ST2 is predominant-
ly expressed on Th2 cells but not naïve T cells, Th1 cells, Th17 
cells and regulatory T cells.
18-20 On the other hand, ST2 is not es-
sential for Th2 cell differentiation as shown in the study using 
ST2-deficient mice; ST2-deficient mice showed the normal de-
velopment of Th2 cells.
21,22 In support for the notion, although 
IL-33 cannot induce the differentiation of Th2 cells from naïve 
CD4
+ T cells in vitro,
23,24 IL-33 can enhance IL-5 and IL-13 pro-
duction by in vitro-skewed Th2 cells which highly express 
ST2.
6,25,26 Also, Kurowska-Stolarska et al.
24 reported that IL-33 in-
duces the differentiation of IL-5
+IL-4
- CD4
+ Th cells from naïve 
CD4
+ T cells independently of IL-4, STAT-6 and GATA-3, which 
are important factors for the typical Th2 cell differentiation.
In human, IL-33 potentiates not only Th2-type cytokine pro-
duction but also Th1-type cytokine, IFN-γ, production by pe-
ripheral blood-derived Th2 cells.
27 In addition, IL-33 acts as a 
chemoattractant for Th2 cells, but not Th1 cells, in both human 
and mice.
28
Innate lymphoid cells
Lin- c-Kit
+ Sca-1
+ natural helper cells dwelling in the gut adi-
pose tissue are a newly identified.
29 Natural helper cells consti-
tutively express ST2 and can produce a larger amount of IL-5 
and IL-13 rather than basophils and mast cells in response to 
IL-33. It was shown that IL-33-mediated natural helper cell ac-
tivation was important for formation of goblet cell hyperplasia 
during Nippostrongylus brasiliensis infection.
29 Similar ST2-ex-
pressing non T/non B lymphoid cell types capable of produc-
ing IL-5 and IL-13 in response to IL-33, are subsequently iden-
tified by other investigators.
30,31
Mast cells
Mast cells, which dwell in the mucosal and connective tissues, 
express c-Kit and high affinity IgE receptors (FcεRI), and induce 
IgE-mediated immune responses, are also major targets of IL-
33. Mouse and human mast cells constitutively express ST2.
32-35 
Except IL-3 and stem cell factor (SCF, a ligand for c-kit), which 
are required for mast cell development at least in mouse, IL-33 
is the only cytokine among 45 different cytokines which can di-
rectly provoke cytokine/chemokine (IL-1β, IL-6, IL-13, TNF, and 
MCP-1) secretion from mouse bone-marrow derived cultured 
mast cells without affecting their degranulation.
36,37
Like a murine counterpart, IL-33 can induce cytokine and 
chemokine production, prolong survival and promote cell-ad-
hesion in human cord blood stem cell-derived cultured mast 
cells.
34,35 In addition, IL-33 can augment IgE-mediated cytokine 
production and degranulation by mouse bone-marrow derived 
cultured mast cells and human cord blood stem cell-derived 
cultured mast cells.
34-36,38
Basophils
Another highly FcεRI-expressing cell type, basophils, which 
circulate in the peripheral blood and are potential primary sourc-
es of IL-4,
39,40 are also considered as the major target of IL-33. In 
comparison with Th2 cells and mast cells, human and mouse 
basophils constitutively express ST2 at the relatively low level 
on their cell surface.
23,26,41,42 On the other hand, the expression 
of ST2 on the cell surface of basophils is promoted by stimula-
tion with IL-3.
26
Like the effect of IL-33 on Th2 cells and mast cells, IL-33 alone 
can induce the production of cytokine including Th2-type cyto-
kines and chemokines by basophils and promote cell-adhesion 
and CD11b expression in basophils in human or mice.
26,27,41,42 
IL-33 does not induce degranulation by basophils directly, while 
IL-33 synergistically enhances IgE-mediated degranulation by 
human basophils.
26,41
In addition, IL-33 augments immune responses of basophils 
in human or mice; eotaxin-mediated migration,
41 cytokine se-
cretion in the presence of IL-3, which is a growth factor for ba-
sophils like mast cells,
23,26,27,41-43 and prolongs survival in the 
presence of IL-3 or GM-CSF.
41-43 These observations suggest 
that IL-33 is a potential activator for basophils by enhancing cy-
tokine and chemokine secretion, recruitment and adhesion.
Eosinophils
Peripheral blood eosinophils, compared to neutrophils, are 
preferentially recruited into the tissue at the site of inflamma-
tion in patients with certain IgE-mediated allergic disorders 
such as asthma. Although ST2 expression was barely detectable 
on cell surface of peripheral blood eosinophils in human, ST2 
mRNA and intracellular ST2 protein were detectable in them.
26,
44,45 IL-33 can induce the production of superoxide and IL-8 di-
rectly, and enhance IL-3, IL-5 or GM-CSF-mediated IL-8 pro-
duction by human eosinophils.
26,44
Like mast cells and basophils, IL-33 enhances adhesion of eo-
sinophils by promoting CD11b expression and survival inde-
pendently of IL-4, IL-5, and GM-CSF.
45 Unlike basophils, IL-33 
did not influence eotaxin-mediated migration of eosinophils.
45 
These observations strongly suggest that IL-33 may contribute 
to the pathogenesis of certain allergic disorders accompanied 
by marked accumulation of eosinophils.
Dendritic cells
IL-33 promotes the development of dendritic cells (DCs) from 
bone marrow cells.
46 It has been shown that DCs derived by the 
cultivation of murine bone marrow cells in the presence of GM-
CSF and IL-4 (that is, bone marrow-derived DCs; BMDCs) ex-
press ST2.
47 IL-33 enhances the production of IL-6, but not IL-Oboki et al.
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12, by BMDCs and augments the expression of MHC class II and 
CD86, but not CD80, CD40 and OX40 ligand (OX40L), on the 
cell surface of BMDCs.
47
When naive CD4
+ T cells were co-cultured with BMDCs in the 
presence of IL-33 for 6 to 10 days, IL-5 and IL-13, but not IL-4 
and IFN-γ, were detected in the culture supernatant even with-
out TCR engagements. Since the secreting cytokine profiles (IL-
5 and IL-13, but not IL-4, production) in the settings (BMDCs + 
naïve CD4
+ T cells + IL-33, no antigens) are similar to those by 
IL-5-positive IL-4-negative atypical Th2 cell population or in-
nate lymphoid cell types, IL-33 may enhance the induction of 
these cell types from naïve CD4
+ T cells.
Like IL-33, IL-25 and TSLP are known to be epithelial/mesen-
chymal cytokines inducing Th2-type cytokine-mediated im-
mune responses.
48 Contrast to IL-33, TSLP-activated DCs pro-
motes IL-4-producing Th2 cell differentiation from naïve CD4
+ 
T cells in the presence of TCR engagements through OX40L-
OX40 interaction at least in part.
49,50 IL-25 can enhance TSLP-
stimulated DC-mediated Th2 cell expansion.
51
Unlike IL-33, both TSLP and IL-25 can induce the differentia-
tion of IL-4-producing Th2 cells from naïve CD4
+ T cells after 
TCR engagements dependently of IL-4-IL-4Rα-STAT6 path-
way.
52,53 Therefore, these observations suggest that the role of 
IL-33, TSLP, and IL-25 in T cells and DCs may be different in 
Th2-type cytokine-mediated immune responses; TSLP and IL-
25 may be involved in the preferential induction of antigen-spe-
cific IL-4/IL-5/IL-13-producing Th2 cell-mediated immune re-
sponses, while IL-33 may contribute to the induction of anti-
gen-non specific Th2 cell-mediated immune responses by in-
ducing IL-5/IL-13-, but not IL-4-, producing atypical Th2 cells 
or innate lymphoid cells.
Other cell types
Regarding epithelial mesenchymal cell types, Yagami et al.
54 
have examined IL-33-responsive cells among primary human 
lung tissue cells. They found that ST2 mRNA was expressed in 
both endothelial and epithelial cells but not in fibroblasts or 
smooth muscle cells. Correspondingly, IL-33 promoted IL-8 
production by both endothelial and epithelial cells but not by 
fibroblasts or smooth muscle cells. Transfection of ST2 small 
interference RNA into both endothelial and epithelial cells sig-
nificantly reduced the IL-33-dependent upregulation of IL-8, 
suggesting that IL-33-mediated responses in these cells occur 
via the ST2 receptor.
While Th2 cytokines, such as IL-4, further enhanced ST2 ex-
pression and function in both endothelial and epithelial cells, 
Th2/eosinophil-related cytokines/chemokines were not pro-
duced by these cell types. While the IL-33-mediated production 
of IL-8 by epithelial cells was almost completely suppressed by 
corticosteroid treatment, the effect of corticosteroid treatment 
on the IL-33-mediated responses of endothelial cells was only 
partial.
54
Comprehensive role of IL-33 regarding other cell types and 
diseases other than asthma has been shown in our previous re-
view article.
1
 
IL-33 AND ASTHMA
Lessons from GWAS for asthma
The completion of the Human Genome Project, the HapMap 
project, and technological advances
55 allowed genome-wide 
association studies (GWAS) to more comprehensively identify 
the susceptibility genes for asthma. Although asthma is now 
recognized as a syndrome consisting of heterogeneous disease 
entities,
56 several genes are shown to be susceptible for asthma 
in GWAS. Recent large-scale GWAS all show the genes for IL-33 
(IL33) and ST2 (IL1RL1) are susceptible for asthma onset.
57-61 It 
should be noted that IL33 and IL1RL1 are located in different 
chromosomes, and that only these two genes are consistently 
listed as asthma-susceptible genes in these literatures. Interest-
ingly, susceptible genes for atopy (IgE production) were entire-
ly different from those for asthma including IL33 and IL1RL1.
58
Thus, IL-33 now attracts much attention from all doctors and 
investigators who are involved in asthma research.
Role of IL-33/ST2 in asthma
The levels of soluble ST2 proteins and IL-33 mRNA/proteins 
are increased in sera and tissues from patients with asthma.
27,62-65 
Also, intraperitoneal or intranasal administration of IL-33 in 
mice leads to the induction of inflammation accompanied by 
eosinophils in mucosa of lung and intestine through the IL-13 
and STAT6-dependent pathway.
6,23 The levels of soluble ST2 
protein and IL-33 mRNA are increased in sera and/or lungs in a 
murine asthma model of airway inflammation induced by ov-
albumin (OVA).
66,67
However, the role of ST2 and IL-33 in the induction of OVA-in-
duced airway inflammation in mice is controversial. Especially, 
apparent discrepancy is often found between the studies using 
ST2-deficient mice and the studies using mice treated with an-
ti-ST2 and ST2-Fc fusion proteins.
1
Respiratory function, eosinophilic airway inflammation and 
the levels of serum total IgG1 and IgE were normally observed 
in 129×B6 mixed and BALB/c background-ST2-deficient mice 
sensitized twice with OVA emulsified with alum.
21,24,68 Several 
investigators reported the effect of anti-ST2 mAb (clone 3E10) 
on OVA-induced airway inflammation in BALB/c mice (twice 
sensitization model with OVA/alum). Airway inflammation in-
duced by OVA was attenuated in BALB/c mice treated with the 
3E10 anti-ST2 mAb.
69,70 Likewise, Th2 responses during OVA-in-
duced airway inflammation were reduced in mice treated with 
anti-IL-33 polyclonal Ab.
71
Adoptive transfer with DO11.10 Th2 cells, which express OVA-
specific T cell receptors, into mice results in Th2 cytokine-de-
pendent eosinophilic airway inflammation after intranasal OVA IL-33 and Airway Inflammation AAIR 
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challenge.
72 The airway inflammation was exacerbated when 
BALB/c wild-type mice or BALB/c-Rag-1-deficient mice inject-
ed with ST2-deficient DO11.10 Th2 cells were challenged with 
OVA in comparison with those mice injected with ST2-suffi-
cient DO11.10 Th2 cells.
68 It suggests that IL-33 signals on Th2 
cells may have a regulatory function in OVA-induced airway in-
flammation. Contrast with the study using ST2-deficient 
DO11.10 Th2 cells,
68 administration of the 3E10 anti-ST2 mAb 
or soluble ST2-Fc fusion protein in mice injected with DO11.10 
Th2 cells showed the attenuated airway function and inflam-
mation after OVA challenge.
19,70
The reason for this discrepancy still remains unclear. Howev-
er, it will be clarified by examining as to whether the expression 
of IL1RAcP, which is a signal amplifier and forms receptor com-
plex not only with ST2 but also with IL-1 receptor (IL1R), is ex-
cessive in various immune cell types from ST2-deficient mice 
(Fig. 1).
Lessons from IL-33 gene deficient mice
Since the possibility of excessive IL-1 signaling in ST2 deficient 
mice cannot be ruled out, generation of IL-33 deficient mice 
has long been expected. Oboki et al.
73 have only recently gener-
ated the IL-33 deficient mice. These mice normally develop, 
suggesting that IL-33 does not play a crucial role as a nuclear 
factor in physiological development.
During airway inflammation induced by twice OVA with alum 
sensitization, IL-33
-/- mice showed attenuated eosinophil influx 
into the bronchoalveolar lavage (BAL) fluid and pulmonary in-
flammation. In contrast, IL-4 and IL-5 levels in the BAL fluid 
and serum OVA-specific IgE production were only slightly (i.e., 
not significantly) reduced in IL-33
-/- mice after the last OVA chal-
lenge. IL-33-deficiency also significantly diminished inflam-
matory cell influx into the BAL fluid during airway inflamma-
tion induced by an extract derived house dust mites (HDM).
73
Furthermore, inhalation of papain, a cystein protease allergen 
having strong homology with HDM allergen, Der 1,
74 which can 
induce airway inflammation even in T/B cell-deficient Rag-2
-/- 
mice, induced strong airway eosinophilia even without sensiti-
zation process. Most importantly, papain-induced airway in-
flammation is profoundly abolished in IL-33
-/- mice as well as 
IL-4
-/-IL-13
-/- mice. Therefore, the papain-induced innate air-
way inflammation is IL-33-dependent, and that IL-4 and/or IL-
13 derived from innate inflammatory cells but not T cells are 
important for the event.
73
Taken together, IL-33 is important for inducing antigen-de-
pendent Th2-associated local airway inflammation. However, 
unlike TSLP
17 and IL-1, IL-33 is mostly dispensable for antigen-
specific Th2 cell differentiation and antigen-specific IgE pro-
duction (Fig. 2), although the actual asthma pathogenesis can-
not be compartmentalized; i.e., IL-33 is capable of stimulating 
TSLP production.
75
Oboki et al.
73 also found that IL-33 is involved in the develop-
ment of dextran-induced colitis accompanied by T cell-inde-
pendent epithelial cell damage, but not in streptozocin-induced 
diabetes or Con A-induced hepatitis characterized by T cell-
mediated apoptotic tissue destruction. In addition, IL-33 failed 
Virus, IL-33, IL-13 etc. Protease, LPS etc.
Allergen
IL-13 release
Cell damage
Chemokine
release
Activation of basophils, 
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Fig. 2.  The major role of interleukin-33 (IL-33) in asthma pathogenesis in comparison with thymic stromal lymphopoietin (TSLP). IL-33 is crucial for protease-mediat-
ed innate airway inflammation associated with cell damage, while TSLP profoundly affect the allergen-specific IgE production/Th2 differentiation.Oboki et al.
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to play a substantial role in induction of T cell mediated contact 
and delayed-type hypersensitivity and autoimmune diseases. 
Of note, unnatural up-regulation of acquired immunity often 
seen in ST2-deficient mice is not seen in IL-33-deficient mice.
73
CONCLUSION
Since recent large-scale GWAS all show the genes for IL-33 
and its receptor are susceptible for asthma, IL-33 now attracts 
much attention from all investigators involved in asthma re-
search. IL-33 is important for protease-mediated innate airway 
inflammation and in the late-phase inflammatory responses in 
the lung observed after IgE-mediated reaction without affect-
ing acquisition of antigen-specific memory T cells. Thus, IL-33 
provides a unique therapeutic way for asthma, i.e., ameliorat-
ing innate airway inflammation.
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